Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection
Top Cited Papers
- 15 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 221 (10), 1688-1698
- https://doi.org/10.1093/infdis/jiz656
Abstract
Background. A synergistic effect of combination therapy with favipiravir and oseltamivir has been reported in preclinical models of influenza. However, no data are available on the clinical effectiveness of combination therapy in severe influenza. Methods. Data from 2 separate prospective studies of influenza adults were used to compare outcomes between combination and oseltamivir monotherapy. Outcomes included rate of clinical improvement (defined as a decrease of 2 categories on a 7-category ordinal scale) and viral RNA detectability over time. Subhazard ratios (sHRs) were estimated by the Fine and Gray model for competing risks. Results. In total, 40 patients were treated with combination therapy and 128 with oseltamivir alone. Clinical improvement on day 14 in the combination group was higher than in the monotherapy group (62.5% vs 42.2%; P=.0247). The adjusted sHR for combination therapy was 2.06 (95% confidence interval, 1.30-3.26). The proportion of undetectable viral RNA at day 10 was higher in the combination group than the oseltamivir group (67.5% vs 21.9%; P<.01). No significant differences were observed in mortality or other outcomes. Conclusions. Favipiravir and oseltamivir combination therapy may accelerate clinical recovery compared to oseltamivir monotherapy in severe influenza, and this strategy should be formally evaluated in a randomized controlled trial.Funding Information
- National Key Research and Development Program of China (2018YFC1200102)
- National Science Fund (81425001/H0104)
- National Science and Technology Major Project (2017ZX10204401004, 2017ZX10103004)
- Ministry of Science and Technology (10600100000015001206)
- Tsinghua University-Peking University Joint Center for Life Sciences
This publication has 34 references indexed in Scilit:
- Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia*Critical Care Medicine, 2016
- Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory virusesAntiviral Research, 2016
- Evaluation of Intravenous Peramivir for Treatment of Influenza in Hospitalized PatientsClinical Infectious Diseases, 2014
- In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virusArchiv für die gesamte Virusforschung, 2013
- Favipiravir (T-705), a novel viral RNA polymerase inhibitorAntiviral Research, 2013
- Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA PolymeraseAntimicrobial Agents and Chemotherapy, 2013
- Corticosteroid Treatment in Critically Ill Patients with Pandemic Influenza A/H1N1 2009 InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Viral Clearance and Inflammatory Response Patterns in Adults Hospitalized for Pandemic 2009 Influenza A(H1N1) Virus PneumoniaAntiviral Therapy, 2010
- T-705 (favipiravir) activity against lethal H5N1 influenza A virusesProceedings of the National Academy of Sciences of the United States of America, 2009
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999